Latest news articles

Added 19 days ago Drug news

Eisai acquires US rights from Purdue Pharma to lemborexant for the treatment of multiple sleep-wake disorders.

Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma L.P.’s rights in the worldwide...

Added 1 month ago Drug news

Phase III trial of AVP 786 shows dose response in Alzheimer's agitation

Avanir Pharmaceuticals announced the results from the first study of the company's phase III clinical development program investigating the efficacy, safety and tolerability of AVP 786...

Added 1 month ago Drug news

Phase III (Clarity AD/Study 301) of BAN 2401 is initiated for early Alzheimer's disease

Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN 2401, an anti-amyloid beta...

Search all news articles for Alzheimer's disease and dementia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Transplantation

Transplantation

See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Load more

Guidelines

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs.

Added 8 years ago

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer ’s disease and other dementias

Objectives: To define a practice guideline for biological treatment of dementia and to make transparent the development of the guideline connecting the original data with the resulting recommendations.

Added 8 years ago

EFNS guidelines for the diagnosis and management of Alzheimer's disease

The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care...

Added 9 years ago

Search all guidelines for Alzheimer's disease and dementia
 

Journal articles

Gray Matter Changes Associated With the Development of Delusions in Alzheimer Disease.

Objective: Delusions affect approximately a third of Alzheimer disease (AD) patients and are associated with poor outcomes. Previous studies investigating the neuroanatomic correlates of delusions have yet to reach a consensus...

Added 6 days ago

A novel therapeutic potential of cysteinyl leukotrienes and their receptors modulation in the neurological complications associated with Alzheimer's disease.

Cysteinyl leukotrienes (cysLTs) are member of eicosanoid inflammatory lipid mediators family produced by oxidation of arachidonic acid by action of the enzyme 5-lipoxygenase (5-LOX). 5-LOX is activated by enzyme...

Added 6 days ago

A vaccine against Alzheimer`s disease: anything left but faith?

Areas covered: We provide an overview of the molecular pathology that leads to an increase in Aβ peptide accumulation, of the mechanism of action for antibody mediated therapies and of the therapeutic vaccines that target...

Added 6 days ago

Search all journal articles for Alzheimer's disease and dementia
 

Clinical trials

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia.

Added 5 days ago

Study of BHV-4157 in Alzheimer's Disease (T2 Protect AD)

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily.

Added 5 days ago

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms...

Added 5 days ago

Search all clinical trials for Alzheimer's disease and dementia
 
Alex Keen

Alex studied Biological Sciences at university before joining EPG Health in January 2017, where he works as a digital content manager and editor.

In his spare time, Alex enjoys relaxing with a cool pint in the company of good friends. 

EPAD – Changing the way we think about Alzheimer’s prevention

We spoke to Professor Craig Ritchie of the University of Edinburgh, the poject co-coordinator for EPAD, a collaborative venture that is facilitating meaningful progress in preventative Alzheimer’s therapies. Find out more about the project, its methods, expectations and goals.

CME

Diabetes care, antivirals for flu and dementia risk: update clinical February 2016

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Hallucinations - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Alzheimer's disease: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Alzheimer's disease and dementia